PARIS--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext : MKEA FR0010609263), inventor of Cellvizio, the multidisciplinary optical biopsy platform, today announced results from a prospective multicenter study showing that optical biopsy procedures performed with Cellvizio successfully confirmed the presence of benign pancreatic cysts in 100% of patients where a superficial vascular network was observed. Results of the study were published today in the peer reviewed journal Endoscopy in an article entitled: “A novel approach to the diagnosis of pancreatic serous cystadenoma: needle-based confocal laser endomicroscopy”.
Help employers find you! Check out all the jobs and post your resume.
